PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
PITTSBURGH, Aug. 13, 2025 /PRNewswire/ -- PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced that it was selected by Insmed as part of the network of specialty pharmacies to dispense BRINSUPRI™ (brensocatib), a...
Related Questions
How will the partnership with PANTHERx® Rare Pharmacy affect Insmed's revenue forecasts for BRINSUPRI™?
What is the expected impact of expanded patient access on market penetration for brensocatib in non‑cystic fibrosis bronchiectasis?
Will this partnership improve the drug's uptake timeline compared to competitors' therapies?
How might the partnership influence Insmed's cost of goods sold and gross margins for BRINSUPRI™?
What are the potential risks related to supply chain or pharmacy network execution that could affect sales projections?
How will the partnership affect Insmed's competitive positioning against other specialty treatments for bronchiectasis?
What is the anticipated effect of this news on INSM stock price in the short and medium term?
Will the partnership impact the pricing strategy or reimbursement negotiations for BRINSUPRI™?
How does this partnership align with Insmed's long‑term growth strategy and pipeline development?
Could this collaboration lead to new indications or expanded label opportunities for brensocatib?